18 Months After ACCORD, FDA Says Fenofibrate May Not Lower MI or Stroke

Eighteen months after the ACCORD (Action to Control Cardiovascular Risk in Diabetes ) trial found no benefit for the addition of fenofibrate to simvastatin in patients with type 2 diabetes, the FDA has issued a safety communication. The FDA changed the label for Trilipix (fenofibric acid, Abbott) and is notifying healthcare […]

Leave a Reply

Your email address will not be published.

*